Clinical Trials Directory

Trials / Completed

CompletedNCT01150669

Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia

SCOR in Targeted Therapies for Infant Leukemia Project 3: Targeting FLT3 in Infant Leukemia

Status
Completed
Phase
Study type
Observational
Enrollment
18 (actual)
Sponsor
Children's Oncology Group · Network
Sex
All
Age
2 Years
Healthy volunteers
Not accepted

Summary

This research study is studying lestaurtinib with or with chemotherapy in samples from young patients with leukemia. Studying the effects of lestaurtinib with or without chemotherapy in cell samples from patients with cancer in the laboratory may help doctors learn more about the effects of this treatment on cancer cells. It may also help doctors identify biomarkers related to cancer.

Detailed description

PRIMARY OBJECTIVES: I. Determine the potential of lestaurtinib with or without chemotherapy agents in treating samples from infants with leukemia. II. Determine whether FLT3 protein expression level and/or activation and sensitivity to lestaurtinib differ between subgroups of infants with leukemia. III. Determine whether lestaurtinib activates STAT5, AKT, and RAS-MAPK and other pathways. IV. Determine whether lestaurtinib can synergize with other chemotherapy agents kill infant leukemia cells. OUTLINE: This is a multicenter study. Cryopreserved specimens are studied in vitro with lestaurtinib with or without chemotherapy agents. Samples are analyzed for FLT3 protein expression and/or activation; sensitivity to lestaurtinib with or without chemotherapy agents; and activation of STAT, AKT, and RAS-MAPK and other pathways by western blot. The most effective treatment from this study is then validated in vivo in a NOD/SCID xenograft model.

Conditions

Interventions

TypeNameDescription
OTHERlaboratory biomarker analysisSamples are analyzed in laboratory studies

Timeline

Start date
2010-07-01
Primary completion
2016-05-01
Completion
2016-05-01
First posted
2010-06-25
Last updated
2016-05-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01150669. Inclusion in this directory is not an endorsement.